The product for the treatment of attention-deficit hyperactivity disorder (ADHD) needs no refrigeration or reconstitution at the pharmacy level.
FDA has approved Adzenys ER, an extended release oral suspension (amphetamine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients age 6 or older. Neos Therapeutics of Dallas and Fort Worth, Texas, announced in a statement that the company plans to launch Adzenys ER in January 2018.
According to the statement, Neos Therapeutics is the only company than can offer both branded amphetamine and methylphenidate therapies in extended release dosage forms. When it is available in 2018, Adenzys ER oral suspension will be the third Neos extended release product for ADHD from the company. It needs no refrigeration or reconstitution at the pharmacy. Another form of the product, Adzenys XR-ODT, is a disintegrating tablet.
“This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended-release amphetamine product and provides a different dosage form of our already-approved Adzenys XR-ODT,” said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More